NCT07650916

A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2026-06-29Est. Completion: 2029-09-04

Enrollment target: 564 participants

Contact

Sexually Transmitted Diseases

The aim of this first time in human proof of concept (FTiH-PoC) study was to evaluate safety and reactogenicity, to demo…

Washington D.C., United StatesCompleted May 22, 2025

Risky Sexual BehaviorEmotion RegulationAdolescent Behavior

Using the efficacious iTRAC intervention to enhance emotion regulation competencies as a foundation, this study will cre…

Golden, United StatesEst. completion Aug 8, 2026

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.